Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
暂无分享,去创建一个
A. Fagan | J. Morris | D. Holtzman | V. Buckles | R. Bateman | C. Xiong | W. Klunk | T. Benzinger | D. Coble | Guoqiao Wang | Yan Li | B. Gordon | S. Schindler | J. Morris | J. Morris | C. Xiong
[1] Keith A. Johnson,et al. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation , 2020, Neurology.
[2] D. Minhas,et al. Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories , 2020, Neurobiology of Aging.
[3] F. Alkuraya. Faculty Opinions recommendation of Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[4] Bertrand Morel,et al. Early mechanisms of amyloid fibril nucleation in model and disease-related proteins. , 2019, Biochimica et biophysica acta. Proteins and proteomics.
[5] Sterling C. Johnson,et al. Amyloid duration is associated with preclinical cognitive decline and tau PET , 2019, bioRxiv.
[6] A. Srivastava,et al. β‐Amyloid aggregation and heterogeneous nucleation , 2019, Protein science : a publication of the Protein Society.
[7] A. Fagan,et al. Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network , 2019, Neurobiology of Aging.
[8] Andrei G. Vlassenko,et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies , 2019, Alzheimer's & dementia.
[9] A. Fagan,et al. Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers , 2018, Brain : a journal of neurology.
[10] J. Dukart,et al. Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials , 2018, Alzheimer's & Dementia.
[11] Yi Su,et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.
[12] Chengjie Xiong,et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies , 2018, NeuroImage: Clinical.
[13] E. Mormino,et al. APOE genotype and early β-amyloid accumulation in older adults without dementia , 2017, Neurology.
[14] C A Budgeon,et al. Constructing longitudinal disease progression curves using sparse, short‐term individual data with an application to Alzheimer's disease , 2017, Statistics in medicine.
[15] Chengjie Xiong,et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.
[16] Chengjie Xiong,et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease , 2016, Annals of neurology.
[17] Jerry L. Prince,et al. Individual estimates of age at detectable amyloid onset for risk factor assessment , 2016, Alzheimer's & Dementia.
[18] Michael J Leach,et al. Longitudinal , 2015, The Medical journal of Australia.
[19] Jerry L Prince,et al. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts , 2015, Neurobiology of Aging.
[20] Karen M Rodrigue,et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.
[21] D. Holtzman,et al. Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.
[22] Keith A. Johnson,et al. Partial volume correction in quantitative amyloid imaging , 2015, NeuroImage.
[23] Nick C Fox,et al. Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.
[24] H. Soininen,et al. Harmonized diagnostic criteria for Alzheimer's disease: recommendations , 2014, Journal of internal medicine.
[25] Y. Stern. Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.
[26] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[27] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[28] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[29] W. Klunk,et al. Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease , 2010, Biological Psychiatry.
[30] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[31] J. Morris,et al. The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers , 2006, Alzheimer disease and associated disorders.
[32] J Philip Miller,et al. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI , 2006, Neurology.
[33] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[34] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] J. Miller,et al. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. , 1993, Archives of neurology.
[36] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[37] J. Morris,et al. Clinicopathologic study of Alzheimer's disease: Alzheimer mimics. , 2013, Journal of Alzheimer's disease : JAD.
[38] G. Bedoya,et al. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. , 2003, Annals of neurology.
[39] P. Lansbury,et al. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.